علاج السكري المناعي الذاتي الكامن لدى البالغين: الحفاظ على وظيفة خلايا بيتا المتبقية

References

• Based on the newest evidences, DPP-4 inhibitors and GLP-1RAs might be used in LADA as an add-on therapy to insulin to sustain residual β-cell function, especially in patients with a relative maintenance of C-peptide secretion.
• With respect to LADA, interesting findings emerge from three recent trials, testing the role of sitagliptin, linagliprin, and saxagliptin in preserving β-cell function.
• Insulin sensitizers have been shown to be helpful in subjects with autoimmune diabetes who share more pronounced insulin-resistant traits.
• Thus, insulin sensitizers might be helpful in subjects with LADA who share more pronounced insulin-resistant features.